SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6 effective February 19, 2019 (the "effective Date"). TrovaGene, Inc. Common Stock (TROV) News Headlines | Nasdaq TROV TrovaGene, Inc. Common Stock (TROV) News Headlines. TrovaGene, Inc. Common Stock (TROV) News Headlines. Jan 21, 2020. First Drug For TED Secures Approval, TROV On Watch, EVOK Faces FDA In … Trovagene, Inc. Announces Reverse Stock Split - Corp! Magazine SAN DIEGO, May 31, 2018 /PRNewswire/ — Trovagene, Inc. (NASDAQ:TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, announced today, a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 12, effective June 1, 2018 (the “Effective Date”). 3 Stocks That Are Long Overdue for a Split | The Motley Fool 3 Stocks That Are Long Overdue for a Split A stock split reduces the share price of a company by a factor chosen by its board of directors, and simultaneously increases the number of shares
Stock Split History, a resource for information about stock splits. StockSplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors.
TROV Stock News - Fidelity Apr 03, 2020 · SAN DIEGO, April 1, 2020 Trovagene (TROV), Inc. , a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, announced today that its Phase 1b/2 clinical trial of onvansertib in combination with standard-of-care FOLFIRI/Avastin® for second-line treatment of patients with KRAS-mutated mCRC, will be Trovagene, Inc. - TROV - Stock Price Today - Zacks View TrovaGene, Inc. TROV investment & stock information. Get the latest TrovaGene, Inc. TROV detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
SAN DIEGO, May 31, 2018 /PRNewswire/ — Trovagene, Inc. (NASDAQ:TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor cancers, announced today, a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 12, effective June 1, 2018 (the “Effective Date”).
TRN Split History Trinity Industries (TRN) has 5 splits in our TRN split history database. The first split for TRN took place on September 01, 1993. This was a 3 for 2 split, meaning for each 2 shares of TRN owned pre-split, the shareholder now owned 3 shares.
SPNV - Superior Energy Services - had a 1 for 10 reverse split. NAKD - Naked PHOT - Growlife - had a ticker change to PHOTD, and a 1 for 150 reverse split. XLSY - Cushing TROV - TrovaGene - had a 1 for 6 reverse split. CHYHY - Chr.
Jan 28, 2020 Noble Capital analyst Cosme Ordonez resumes coverage on TrovaGene ( NASDAQ: TROV) with a Outperform rating and a price target of Get today's Trovagene Inc stock price and latest TROV news as well as Trovagene real-time stock quotes, technical analysis, full financials and more.
TrovaGene, Inc. (TROV) Stock Analysis & News | Seeking Alpha
Stock Movers: Why TrovaGene, Inc. (TROV) Stock Is Crushed ...